Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;18(1):1-6.
doi: 10.1016/j.hpb.2015.07.008. Epub 2015 Nov 30.

A systematic review of safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers

Yanming Zhou  1 , Zuobing Zhang  2 , Lupeng Wu  2 , Bin Li  2
Affiliations

A systematic review of safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers

Yanming Zhou et al. HPB (Oxford). 2016 Jan.

Abstract

Objectives: To review the evidence on the safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers.

Methods: Medline and EMBASE were systematically searched for papers of hepatopancreatoduodenectomy in patients with biliary and gallbladder cancers.

Results: Eighteen studies involving 397 patients were reviewed. Major hepatectomy was undertaken in 81.3% of the 397 patients and the R0 resection rate was 71.3%. The morbidity and mortality rates were 78.9% and 10.3%, respectively. The 5-year overall survival rate ranged from 3% to 50% (median = 31%). The 5-year survival rate in patients who underwent curative resection was 18-68.8% (median = 51.3%), and 0% in patients who received non-curative resection.

Conclusions: Hepatopancreatoduodenectomy is a challenging procedure with high morbidity and mortality rates. However, this procedure can provide a chance of long-term survival in patients in whom curative resection is feasible.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram for the selection of eligible studies
Figure 2
Figure 2
Flow diagram of operative indications and strategies to reduce surgical risk of hepatopancreatoduodenectomy. BC, bile duct cancer; GC, gallbladder cancer; BD, biliary drainage; a, ≤20% in normal liver, ≤30% with significant fibrosis or steatosis, and ≤40% in cirrhosis; b, soft pancreatic texture and a nondilated pancreatic duct
See this image and copyright information in PMC

References

    1. Ishikawa T., Horimi T., Shima Y., Okabayashi T., Nishioka Y., Hamada M. Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder. J Hepatobiliary Pancreat Surg. 2003;10:233–238. - PubMed
    1. Seyama Y., Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol. 2007;13:1505–1515. - PMC - PubMed
    1. Nimura Y., Hayakawa N., Kamiya J., Maeda S., Kondo S., Yasui A. Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology. 1991;38:170–175. - PubMed
    1. Nakamura S., Nishiyama R., Yokoi Y., Serizawa A., Nishiwaki Y., Konno H. Hepatopancreatoduodenectomy for advanced gallbladder carcinoma. Arch Surg. 1994;129:625–629. - PubMed
    1. Tsukada K., Yoshida K., Aono T., Koyama S., Shirai Y., Uchida K. Major hepatectomy and pancreatoduodenectomy for advanced carcinoma of the biliary tract. Br J Surg. 1994;81:108–110. - PubMed

Publication types

MeSH terms